Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (1-10 of 410) with videos related to

Pageof 41
Sort By:
World Journal of Urology|February 22, 2005
Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancerKim N Chi
Microbiologyopen|June 29, 2022
Solution nuclear magnetic resonance spectroscopy of bacterial outer membrane proteins in natively excreted vesicles using engineered Escherichia coliMohammed Mouhib, Celestine N Chi
Future Oncology (London, England)|November 8, 2012
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancerRobert Zielinski, Kim N Chi
Annals of the New York Academy of Sciences|January 6, 2006
Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancersMartin Gleave, Kim N Chi
International Journal of Urology : Official Journal of the Japanese Urological Association|June 28, 2016
Chemotherapy for metastatic castration-sensitive prostate cancerSunil Parimi, Kim N Chi
The Journal of Urology|June 1, 1985
Balanitis as a fixed drug eruption to tetracyclineP R Dodds, T N Chi
The Urologic Clinics of North America|February 16, 2010
Novel targeted therapies for prostate cancerRobyn J Macfarlane, Kim N Chi
Current Oncology (Toronto, Ont.)|October 1, 2010
Research in castration-resistant prostate cancer: what does the future hold?R J Macfarlane, K N Chi
Current Opinion in Supportive and Palliative Care|August 8, 2008
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancerEmma K Beardsley, Kim N Chi
Expert Opinion on Biological Therapy|June 4, 2004
Antisense approaches in prostate cancerKim N Chi, Martin E Gleave
Pageof 41

Showing results (1-10 of 410) with videos related to

Sort By:
Pageof 41
World Journal of Urology|February 22, 2005
Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancerKim N Chi
Microbiologyopen|June 29, 2022
Solution nuclear magnetic resonance spectroscopy of bacterial outer membrane proteins in natively excreted vesicles using engineered Escherichia coliMohammed Mouhib, Celestine N Chi
Future Oncology (London, England)|November 8, 2012
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancerRobert Zielinski, Kim N Chi
Annals of the New York Academy of Sciences|January 6, 2006
Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancersMartin Gleave, Kim N Chi
International Journal of Urology : Official Journal of the Japanese Urological Association|June 28, 2016
Chemotherapy for metastatic castration-sensitive prostate cancerSunil Parimi, Kim N Chi
The Journal of Urology|June 1, 1985
Balanitis as a fixed drug eruption to tetracyclineP R Dodds, T N Chi
The Urologic Clinics of North America|February 16, 2010
Novel targeted therapies for prostate cancerRobyn J Macfarlane, Kim N Chi
Current Oncology (Toronto, Ont.)|October 1, 2010
Research in castration-resistant prostate cancer: what does the future hold?R J Macfarlane, K N Chi
Current Opinion in Supportive and Palliative Care|August 8, 2008
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancerEmma K Beardsley, Kim N Chi
Expert Opinion on Biological Therapy|June 4, 2004
Antisense approaches in prostate cancerKim N Chi, Martin E Gleave
Pageof 41